Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epigenetic agents + pembrolizumab + epacadostat in advanced solid tumors
NCT02959437Phase 2Terminated
- Sponsor
- Incyte
- Start
- Feb 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of epacadostat in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC) and 2 more (3 arms), sponsored by Incyte. Primary endpoints: Treatment Emergent Adverse Events and Objective Response Rate. Started Feb 2017; status: terminated.
02
Drugs
epacadostat
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)urothelial carcinoma (UC)melanoma
Beyond the preview
Go deeper on NCT02959437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959437.